Peptides For Body Composition: What The Evidence Actually Shows

The peptides sold for body composition aren’t the sure things the marketing implies. AOD-9604 flunked its largest human weight-loss trial. MOTs-C has never finished one. Sermorelin was an FDA-approved drug once, then pulled from the market in 2009. At Revive 365 Wellness in Weston, we use four of them, CJC-1295 with ipamorelin, sermorelin, AOD-9604, and MOTs-C, for body composition, the balance of fat and muscle your body carries, as supervised tools with monitoring, not fat-melting shots. This piece separates what each one has actually shown in people from what’s still only shown in mice, and lays out where the law stands in 2026.

Peptides for body composition are short amino-acid chains used to shift the ratio of fat to muscle rather than just lower the scale. The ones used most often, CJC-1295, ipamorelin, sermorelin, AOD-9604, and MOTs-C, act on growth-hormone signaling or fat metabolism. Only sermorelin was ever FDA-approved, and that approval was withdrawn, so today all of them are prescribed as compounded medications under a provider’s supervision.

Why the scale is the wrong scoreboard

Two people at the same weight can have very different metabolic futures, because weight says nothing about what that weight is made of. The number that tracks with health is the split between fat and muscle, and where the fat sits. Fat packed deep around the organs, called visceral fat, behaves differently from the fat just under your skin. Harvard Health has documented that this deep abdominal fat is the metabolically active kind, the sort linked to insulin resistance, higher blood pressure, and heart disease.

Muscle does the opposite work. It pulls glucose out of your blood, holds up your resting metabolism, and tends to track with better long-term outcomes. So the goal isn’t a smaller number on the scale. It’s less visceral fat and more retained muscle. That distinction is the entire reason peptides enter the conversation, and it’s also why a good medical weight-loss program measures more than pounds.

The muscle problem with GLP-1 shots

Most weight-loss clinics won’t put this in writing: the GLP-1 medications everyone’s taking can strip muscle along with fat. In a body-composition analysis of the STEP 1 semaglutide trial, participants lost about 19% of their fat mass, but also close to 10% of their lean mass over 68 weeks. A meaningful share of the weight people cheer about is muscle walking out the door.

There’s a fairer reading, too. Because fat fell faster than muscle, lean tissue actually made up a slightly larger share of body weight by the end. So the “Ozempic wastes your muscle” panic is overstated. But the risk is real for anyone who loses weight fast without resistance training or enough protein. The proven levers for protecting muscle are lifting and protein, full stop. Whether adding a growth-hormone-stimulating peptide preserves more lean mass on a GLP-1 hasn’t been settled in human trials, and we won’t pretend it has. If you’re weighing the medications, our breakdown of who qualifies for GLP-1 treatment covers that side.

The peptides we use, and what the research really shows

We work with four in this space. Here’s the honest scorecard, evidence and legal status included.

Peptide	Class	What it’s theorized to do	Human evidence	FDA / compounding status (2026)
Sermorelin	GHRH analog	Prompt the pituitary to release growth hormone; positioned for muscle tone, energy, and mental clarity	Small studies, mostly in older adults, show higher IGF-1 and modest lean-mass gains. Cognition results are mixed.	Formerly FDA-approved (Geref, withdrawn 2009 for business reasons). Now compounded, and the cleanest status of the group.
CJC-1295 + ipamorelin	GHRH analog plus GH secretagogue	Raise your own growth hormone in natural pulses, which may support lean mass and fat metabolism	Short pharmacology studies confirm they raise growth hormone and IGF-1. No large trials measuring actual body-composition change.	Not FDA-approved. Compounded; eligibility unsettled and under review.
AOD-9604	Fragment of growth hormone	Trigger fat breakdown (lipolysis) without raising blood sugar	Six human trials, 900+ participants. The largest, a Phase 2b obesity study, did not beat placebo on weight loss. Dropped as a drug candidate.	Not FDA-approved. Under FDA compounding review.
MOTs-C	Mitochondrial-derived peptide	Improve insulin sensitivity and copy some effects of exercise	Strong animal data. In lab studies it raised insulin-stimulated glucose uptake by roughly 30%. Human data is limited to correlations, no completed efficacy trials.	Not FDA-approved. Reviewed by the FDA’s compounding advisory committee in July 2026.

A few plain-language takeaways from that table.

Sermorelin is the most established of the four, and the only one with a real regulatory past. The FDA approved it in the 1990s as Geref for a pediatric growth-hormone test, then the maker withdrew it in 2009 for business reasons, not safety. Small studies in older adults tie it to higher IGF-1 and modest lean-mass gains, with mixed results on memory and focus. Revive 365 groups sermorelin with CJC/IPA under performance and vitality, for muscle tone, energy, and mental clarity. The muscle and growth-hormone piece has the most behind it. The energy and cognition claims rest on small, older-adult studies, so we treat them as plausible, not promised.

CJC-1295 with ipamorelin is the pair with the cleanest rationale but the thinnest proof. They reliably raise growth hormone. What’s missing is the study showing that translates into measured fat-down, muscle-up change over months. We use them as a lever on growth-hormone signaling, not as a guarantee.

AOD-9604 is the clearest case of hype running ahead of data. It was engineered as the fat-burning fragment of growth hormone, the animal results looked promising, and then the human trials didn’t deliver. Anyone selling it as a proven fat-loss shot is ignoring its own trial record.

MOTs-C is the most interesting and the least proven. The mitochondrial biology is real and the animal work is strong, but “works in mice” and “works in people” are different sentences. It’s early.

For contrast, the peptide in this family with the strongest body-composition data, tesamorelin, is FDA-approved, but only for HIV-related visceral fat, and only after trials that measured it on CT scans. Sermorelin’s old approval was for a different job entirely. So none of the four we use is approved for what you’d actually want it for here. That doesn’t make them worthless. It places them earlier on the evidence curve, which is exactly why supervision and measurement matter more, not less. If you want the wider map, we keep a guide to the different types of peptide therapy.

Are these peptides FDA-approved or legal in 2026?

None of the four is FDA-approved for body composition. Sermorelin is the one with an asterisk, since it held approval in the past as Geref before the maker pulled it in 2009 for business reasons. The rest, CJC-1295, ipamorelin, AOD-9604, and MOTs-C, were never approved. All of them are used today as compounded medications, made by a licensed pharmacy on a prescription, and that pathway is unsettled. The FDA restricted several of these peptides in 2023, reversed course in 2024, and its advisory committee took up MOTs-C and related peptides in July 2026. There’s no final rule yet. Sermorelin sits in the most settled spot of the group, MOTs-C the least.

What that means for you: this is a category where the provider’s judgment and sourcing matter. Compounded is not the same as approved, and a clinic that glosses over that isn’t being straight with you.

How we use peptides for body composition at Revive 365

We start with data, not a prescription. That means baseline labs, including IGF-1 and metabolic markers, and a body-composition scan so we can see visceral fat and lean mass instead of guessing from the scale. We set a target that’s a composition target, then re-measure and adjust. If the numbers don’t move, the protocol changes or stops.

That approach is the actual product here, more than any single molecule. The peptides are early-evidence tools; the monitoring, dosing, and lab work are what make using them defensible. That’s why we run this inside a provider-led peptide therapy program, part of our Weston wellness services, rather than shipping vials and wishing you luck.

Who’s a candidate, and who isn’t?

Good candidates tend to share a pattern: central fat that resists diet and exercise, or muscle loss during a GLP-1 course, plus a willingness to lift and eat enough protein while under monitoring. If you’ll do the work and want composition tracked properly, this can fit.

It’s a poor fit for plenty of people, and we’d rather say so. If you’re pregnant or breastfeeding, have an active cancer, or carry certain hormone-sensitive conditions, these are off the table. If you want an unsupervised shortcut, we’re not your clinic. And if resistance training and protein aren’t going to happen, no peptide rescues that. Before anyone starts, it’s worth reading what to weigh before starting peptide therapy.

What results can you realistically expect?

Less than the ads promise and more than nothing, with wide variation. Because the human body-composition evidence for these peptides is thin, we don’t hand out a pounds-per-month figure. We track visceral fat and lean mass and judge the protocol by whether those move. If you want the scale-weight version of this question, our companion piece on how much weight peptide therapy can take off covers expectations there. On composition, the win is a smaller waist with your muscle intact, confirmed by measurement, not a guess.

The honest version of peptides for body composition is less thrilling than the marketing and far more useful. The scale is the wrong scoreboard, most of these molecules are still early in their evidence, and the results that hold up come from measuring body composition, protecting muscle, and adjusting with a provider who watches both. If a clinic promises you a fixed number of pounds from a peptide, that’s the tell.

Disclaimer: This content is for informational purposes only and is not intended as medical advice. Peptide therapy should only be considered under the guidance of a licensed healthcare professional. Individual results may vary.

FAQs

Are peptides for body composition FDA-approved?

No, with one asterisk. CJC-1295, ipamorelin, AOD-9604, and MOTs-C are not FDA-approved for body composition or weight, and are used as compounded medications. Sermorelin once held FDA approval (as Geref) but was withdrawn in 2009 for business reasons and is now compounded too. The FDA’s advisory committee reviewed MOTs-C in July 2026, with no final rule yet.

How is sermorelin different from CJC-1295 and ipamorelin?

All three prompt your body to release its own growth hormone, but sermorelin has the longest track record and the cleanest compounding status, because it was an approved drug in the past. Small studies in older adults link it to higher IGF-1 and modest lean-mass gains. CJC-1295 and ipamorelin reliably raise growth hormone but lack trials measuring actual body-composition change.

Can peptides reduce visceral (belly) fat?

The evidence is mixed and mostly early. The only growth-hormone-releasing peptide with strong visceral-fat data, tesamorelin, is FDA-approved solely for HIV-related fat. The peptides used in wellness settings, including the four we work with, lack large trials measuring visceral-fat change, which is why we track it with a scan rather than assume it.

Do peptides protect muscle while I’m on Ozempic or Wegovy?

Not proven. In the STEP 1 semaglutide trial, lean mass dropped close to 10% alongside about 19% fat loss, so muscle loss on GLP-1s is a real concern. The established protections are resistance training and adequate protein. Whether a peptide adds to that in humans hasn’t been shown in trials.

Does AOD-9604 actually work for weight loss?

Its track record is weak. AOD-9604 went through six human trials, and the largest, a Phase 2b obesity study, did not outperform placebo, which ended its path to becoming an approved drug. We’re upfront about that rather than marketing it as a proven fat burner.

What is MOTs-C, and is it proven in people?

MOTs-C is a peptide encoded in mitochondrial DNA that improves insulin sensitivity in animal studies and raised glucose uptake by roughly 30% in lab models. Human evidence is limited to correlations, with no completed efficacy trials, so it’s best seen as experimental.

Is peptide therapy for body composition safe?

It should only be done under a licensed provider who monitors labs and adjusts dosing, because these are compounded, not FDA-approved, products. Reported side effects include injection-site reactions and changes in blood-sugar markers. This content is informational and not medical advice; individual results vary.